A Systematic review for sudden cardiac death in hypertrophic cardiomyopathy patients with Myocardial Fibrosis: A CMR LGE Study
Article Sidebar
Main Article Content
Abstract
Background: Hypertrophic cardiomyopathy (HCM) patients have a predisposition for malignant VT/VF and consequently, sudden cardiac death (SCD). In single center studies, late gadolinium enhancement (LGE) defined fibrosis has been linked to VT/VF. However, despite innumerable investigations, SCD has not been definitely attributable to LGE. Explanations for these are believed to be related to insufficient statistical power.
Methods: We performed an electronic search of MEDLINE, PubMed: and CMR abstracts for original data published or presented between Jan 2001 to Mar 2011. Key search terms: HCM, LV fibrosis, SCD and LGE. Studies were screened for eligibility based on inclusion criteria: referral for CMR exam with LGE for HCM; and follow-up for incidence of VT/VF and SCD. Categorical variables were evaluated between patient groups via Chi-square test.
Results: A total of 64 studies were initially identified. Of these, 4 (6.3%) were identified and included (n = 1063 patients). Three prospective and one retrospective study were included. LGE was detected in 59.6% of patients. As expected, the presence of myocardial fibrosis was associated with VT/VF (x2 = 6.5, p < 0.05; OR 9.0, (95% CI 1.2 to 68.7). Moreover, myocardial fibrosis strongly predicted SCD (x2 = 6.6, p < 0.05; OR 3.3 (95% CI 1.2 to 9.7).
Conclusion: Despite single center CMR studies, LGE has consistently predicted VT/VF while prediction of SCD has remained paradoxically unlinked. Although the lack of studies meeting our criteria limited our ability to perform a comprehensive meta-analysis, we have been able to demonstrate for the first time that LGE-defined fibrosis is a predictor of SCD in patients with HCM0.
Article Details
Copyright (c) 2019 Reddy ST, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Cardiology and Cardiovascular Medicine is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Cardiology and Cardiovascular Medicine is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Circulation. 1995; 92: 785-789. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7641357
Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995; 92: 1336-1347. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7648684
Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19:104-10. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17916152
Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995; 92: 1680-1692. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7671349
Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002; 287: 1308-1320. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11886323
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000 ;36: 2212-2218. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11127463
Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102: 858-864. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10952953
Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, et al. Implantable Cardioverter-Defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007; 298: 405-412. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17652294
Biederman RWW, Doyle M, Yamrozik J. Cardiovascular MRI tutorials: Lectures and Learning. Lippincott Williams et al. & Wilkins 2007.
Amin NN, Grant SB, Yamrozik JA, Williams RB, Thompson DV, et al. The Concordance Rates between LV Hypertrophy and RV Hypertrophy in Patients with Hypertrophic Cardiomyopathy as Diagnosed by Cardiovascular MRI with Fibrosis Imaging. World J of Cardiovasc Dis. 2015; 5: 171-180.
Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009; 54: 242-249. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19589437
Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008; 51: 1369-1374. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18387438
Kwon DH, Setser RM, Popović ZB, Thamilarasan M, Sola S, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 2008;24:617-625. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18204915
Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56: 875-887. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20667520
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, et al. 2011 ACCF/AHA Guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: a report for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011; 58: e212-260. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22068435
Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010; 3: 51-58. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19850699
O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56: 867-874. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20688032
Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008; 1: 184-191. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19808288
Elliot P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-1991. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15183628
Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:261-267. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20599013
Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12957435